Compare Cassava Sciences Inc (FLNA) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs T-Mobile Us Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while T-Mobile Us Inc trades at $192.42 (market cap $203.04B). The key difference: T-Mobile Us Inc is far larger — about 3820.9× Cassava Sciences Inc's market cap, and T-Mobile Us Inc pays a 2.17% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TMUS | |
|---|---|---|
Market Cap | $53.14M | $203.04B |
Sector | Health | Media |
52-Week High | $4.64 | $259.01 |
52-Week Low | $1.09 | $167.65 |
Enterprise Value | -$33.43M | $320.74B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
T-Mobile US (TMUS) trades at $187.13, down 0.68% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The company reported strong Q1 2026 earnings of $2.27 per share, beating expectations, and maintains robust fundamentals with 2025 revenue of $88.31 billion and net income of $10.99 billion. Recent leadership changes and positive analyst coverage highlight ongoing strategic growth initiatives.
The outlook for TMUS remains positive with an 83% analyst buy rating and a consensus price target of $241.27, suggesting significant upside. Key risks include rising debt levels, competitive pressures from satellite internet providers like Starlink, and potential margin compression. The stock presents a growth opportunity supported by strong cash flow and market positioning, though investors should monitor execution against these challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
